Has Apotex's Ruxolitinib ANDA Been Approved?
No, Apotex's Abbreviated New Drug Application (ANDA) for ruxolitinib phosphate topical suspension has not received final FDA approval as of the latest available data. The FDA issued a Complete Response Letter (CRL) in March 2024, citing issues with chemistry, manufacturing, and controls (CMC) that prevented approval.[1][2]
What Was the CRL About?
The CRL focused solely on CMC deficiencies at Apotex's manufacturing facility, with no concerns raised about the drug's safety, efficacy, or bioequivalence to Incyte's Opzelura (ruxolitinib cream 1.5%). Apotex plans to address these and resubmit, potentially leading to approval later.[1][3]
When Did Apotex File and Get Tentative Approval?
Apotex submitted its ANDA in December 2021 and received tentative approval on October 6, 2023. This tentative status means the application meets all standards except for unresolved patent or exclusivity issues blocking final approval.[1][2]
What's Holding Up Final Approval?
Patent litigation with Incyte remains the primary barrier. Incyte sued Apotex in 2022 over U.S. Patent No. 10,898,467 (expires 2027) and others covering Opzelura's formulation. A settlement in November 2023 allows Apotex a launch no earlier than January 1, 2031, or earlier under certain conditions.[2][4] No pediatric exclusivity blocks entry before May 2027.[1]
Any Recent FDA Updates or Resubmissions?
Apotex has not publicly confirmed a resubmission post-CRL. Check FDA's Orange Book or Drugs@FDA for updates, as approvals can change quickly. DrugPatentWatch lists the ANDA (205571) as tentatively approved with ongoing litigation.[1]
How Does This Compare to Other Ruxolitinib Generics?
Other filers like Dr. Reddy's (ANDA 217709) also have tentative approvals for ruxolitinib cream but face similar patent challenges. No generic ruxolitinib topicals are fully approved yet, preserving Incyte's market exclusivity for Opzelura.[1][5]
Sources
[1]: DrugPatentWatch.com - Ruxolitinib Phosphate Topical Suspension
[2]: FDA Paragraph IV Patent Certifications
[3]: Apotex Press Release, March 2024
[4]: Incyte v. Apotex Settlement, Nov 2023
[5]: DrugPatentWatch.com - Opzelura Generics